Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 1
2015 2
2016 4
2017 3
2018 4
2019 5
2020 9
2021 11
2022 13
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Upfront neck dissection for treatment selection and improvement in quality of life as a novel treatment paradigm for deintensification in HPV+ OPSCC.
Swiecicki PL, Bellile E, Dragovic AF, McHugh J, Udager A, Mierzwa ML, Shah J, Heft Neal M, Rosko A, Malloy KM, Casper K, Chinn SB, Shuman AG, Stucken C, Chepeha DB, Wolf GT, Bradford CR, Eisbruch A, Prince MEP, Worden FP, Spector ME. Swiecicki PL, et al. Clin Cancer Res. 2024 Mar 22. doi: 10.1158/1078-0432.CCR-23-3247. Online ahead of print. Clin Cancer Res. 2024. PMID: 38517480
ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancer.
Bhambhani C, Kang Q, Hovelson DH, Sandford E, Olesnavich M, Dermody SM, Wolfgang J, Tuck KL, Brummel C, Bhangale AD, He K, Gutierrez MG, Lindstrom RH, Liu CJ, Tuck M, Kandarpa M, Mierzwa M, Casper K, Prince ME, Krauss JC, Talpaz M, Henry NL, Giraldez MD, Ramnath N, Tomlins SA, Swiecicki PL, Brenner JC, Tewari M. Bhambhani C, et al. Among authors: swiecicki pl. JCI Insight. 2024 Feb 8;9(6):e177759. doi: 10.1172/jci.insight.177759. JCI Insight. 2024. PMID: 38516891 Free PMC article.
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. Ferrarotto R, et al. Among authors: swiecicki pl. Oral Oncol. 2024 Feb;149:106634. doi: 10.1016/j.oraloncology.2023.106634. Epub 2023 Dec 20. Oral Oncol. 2024. PMID: 38118249 Free article. Clinical Trial.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Among authors: swiecicki pl. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.
Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
Bhambhani C, Sandford E, Haring CT, Brummel C, Tuck KL, Olesnavich M, Bhangale AD, Walline HM, Dermody SM, Spector ME, Chinn SB, Casper K, Mierzwa M, Swiecicki PL, Chad Brenner J, Tewari M. Bhambhani C, et al. Among authors: swiecicki pl. Oral Oncol. 2023 Aug;143:106436. doi: 10.1016/j.oraloncology.2023.106436. Epub 2023 Jun 1. Oral Oncol. 2023. PMID: 37269557
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Pasternak AL, Seda R, Lipa J, McDevitt RL, Crysler OV, Swiecicki PL, Schneider BJ, Vanderwerff B, Henry NL, Krauss JC, Sahai V, Hertz DL. Pasternak AL, et al. Among authors: swiecicki pl. Clin Pharmacol Ther. 2023 Aug;114(2):356-361. doi: 10.1002/cpt.2936. Epub 2023 May 30. Clin Pharmacol Ther. 2023. PMID: 37163252
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Haring CT, Kana LA, Dermody SM, Brummel C, McHugh JB, Casper KA, Chinn SB, Malloy KM, Mierzwa M, Prince MEP, Rosko AJ, Shah J, Stucken CL, Shuman AG, Brenner JC, Spector ME, Worden FP, Swiecicki PL. Haring CT, et al. Among authors: swiecicki pl. Cancer. 2023 Sep 15;129(18):2817-2827. doi: 10.1002/cncr.34823. Epub 2023 May 10. Cancer. 2023. PMID: 37162461
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Smith JD, Ludwig ML, Bhangale AD, Brummel C, Swiecicki PL, Worden FP, Chinn SB, Stucken CL, Rosko AJ, Prince MEP, Malloy KM, Casper KA, Bradford CR, Chepeha DB, Shah J, Schonewolf CA, McHugh JB, Nyati MK, Eisbruch A, Mierzwa ML, Spector ME, Brenner JC. Smith JD, et al. Among authors: swiecicki pl. Head Neck. 2023 May;45(5):1281-1287. doi: 10.1002/hed.27344. Epub 2023 Mar 18. Head Neck. 2023. PMID: 36932871 Clinical Trial.
Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis.
Allen SG, Rosen BS, Aryal M, Cao Y, Schipper MJ, Wong KK, Casper KA, Chinn SB, Malloy KM, Prince ME, Rosko AJ, Shuman AG, Spector ME, Stucken CL, Swiecicki PL, Worden FP, Brenner JC, Schonewolf CA, Elliott DA, Mierzwa ML, Shah JL. Allen SG, et al. Among authors: swiecicki pl. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):171-180. doi: 10.1016/j.ijrobp.2023.03.043. Epub 2023 Mar 16. Int J Radiat Oncol Biol Phys. 2023. PMID: 36931572 Clinical Trial.
54 results